New drug reduces Alzheimer’s protein levels in clinical trial

In results from a phase 1 clinical trial published today (Wednesday 2 November), a potential new drug called verubecestat has been shown to reduce levels of the Alzheimer’s protein amyloid in brain and spinal fluid in people with Alzheimer’s disease. The results are published in Science Translational Medicine.